Hematology

A venetoclax-based AML regimen produced high remission rates and prolonged survival in older or unfit patients with newly diagnosed acute myeloid leukaemia.

A gene edited AML transplant strategy achieved rapid engraftment and supported targeted maintenance therapy without prolonged high grade cytopenias in high risk disease.

Longitudinal data showed hydroxyurea adherence declined steadily among patients with sickle cell disease, particularly in older age groups and those with executive difficulties.

Targeting PELI1 in chronic myeloid leukaemia may overcome treatment resistance and eliminate leukaemia stem cells, offering a promising new therapeutic strategy.

TP53 multihit alterations show reduced impact in del(5q) myelodysplastic neoplasms, with improved survival and delayed progression to acute myeloid leukaemia.

CRISPR gene therapy shows improved haemoglobin levels and reduced vaso occlusive events in severe sickle cell disease in early phase study data.

A new conditioning regimen for sickle cell transplantation shows high survival, strong engraftment, and low graft versus host disease in adolescents and adults.

The PASS aplastic anaemia diagnostic tool accurately differentiates acquired disease from inherited syndromes, enabling rapid clinical decision making using routine data.